好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Translating Logistical Challenges into Service Improvement: MS Infusional Services during the Covid-19 Pandemic
Multiple Sclerosis
MS and CNS Inflammatory Disease Posters (7:00 AM-5:00 PM)
236

To assess patient satisfaction with delivery of MS infusional therapies at the new location, supervised by specialist MS nurses, compared to the previous delivery of treatments at the Regional Centre, which had limited input from the MS nursing team but was delivered by infusional nurses.

Providing safe and effective care to Multiple Sclerosis (MS) patients has been a challenge during the Covid-19 pandemic. Across Northern Ireland, surge plans necessitated an abrupt change of facility for MS infusional services from the Royal Victoria Hospital (RVH) to a non-acute site at Musgrave Park Hospital (MPH). The MS specialist nursing team moved to deliver the service in an unfamiliar setting.

A questionnaire was developed to survey patient experience of the revamped service, which patients were invited to complete upon attendance for infusion. Patient consent was implied by completion of the questionnaire. Data collected included demographics and levels of service satisfaction across various headings.

In total, 120 responses were received (100% return) indicating a strong preference for the new service arrangement in MPH. Overall, 97% recorded a satisfaction score of ≥8/10 (0-10, 10 = extremely satisfied). Key areas of improvement at MPH were: difficulty parking (0.8% vs 50% in RVH), difficult access to the unit (0.8% vs 38% previously), appointment punctuality (95% on time vs 35% previously), and comfort (83% vs 55% previously). Thematic analysis revealed positive free-text feedback centred on: improved access to MS nursing knowledge, improved cannulation skills, and time-keeping. The most frequent (46%) suggestion for improvement was more comfortable seating.

This study demonstrates very strong satisfaction with the relocated infusional service. Better service access and specialist nursing input were associated with clear improvements in patient experience. This study illustrates the unique opportunity for service improvement during a time of unprecedented pressure on healthcare systems.
Authors/Disclosures
Stephen J. Ramsay, MB (UK) (Royal Victoria Hospital, Belfast Health and Social Care Trust)
PRESENTER
Dr. Ramsay has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
Jon D. McKee, MBBS (Craigavon Hospital) Dr. McKee has nothing to disclose.
Fiona Kennedy, MB, Bch, BAO Dr. Kennedy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Kennedy has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Kennedy has received personal compensation in the range of $500-$4,999 for serving as a Meeting chair with Neuraxpharm. Dr. Kennedy has received personal compensation in the range of $500-$4,999 for serving as a Meeting chair with Roche. Dr. Kennedy has received personal compensation in the range of $0-$499 for serving as a Meeting chair with Merck. Dr. Kennedy has received personal compensation in the range of $500-$4,999 for serving as a Conference delegate with Sanofi. Dr. Kennedy has received personal compensation in the range of $500-$4,999 for serving as a Conference delegate with Novartis. Dr. Kennedy has received personal compensation in the range of $500-$4,999 for serving as a Conference delegate with Roche.
Aidan G. Droogan, BSc, MBB (Belfast HSC Trust (RVH)) Dr. Droogan has nothing to disclose.
Stella E. Hughes, MD Dr. Hughes has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Merck. Dr. Hughes has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Hughes has received personal compensation in the range of $500-$4,999 for serving as a Meeting Chair with Merck. Dr. Hughes has received personal compensation in the range of $500-$4,999 for serving as a Speaker with Biogen. Dr. Hughes has received personal compensation in the range of $500-$4,999 for serving as a Meeting Chair with Roche. Dr. Hughes has received personal compensation in the range of $500-$4,999 for serving as a Conference Delegate with Roche.
Gavin V. McDonnell, MD (Belfast Trust) Dr. McDonnell has nothing to disclose.